Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Dorothée Meric"'
Autor:
S. Rachel Skinner, Henry C Kitchener, Gary Dubin, Jorge Salmerón, Margaret E. Cruickshank, Frank Struyf, Wim Quint, Dominique Descamps, Myron J. Levin, Eduardo Lazcano-Ponce, René H.M. Verheijen, Daniel da Silva, Céline Bouchard, Swee Chong Quek, Karin Hardt, Anne Szarewski, Kah Leng Fong, Arunachalam Ilancheran, Barbara Romanowski, Jack T. Stapleton, Dorothée Meric, M. Rowena Del Rosario-Raymundo, Brecht Geeraerts, Deborah Money, Mark G. Martens, Archana Chatterjee, Marie Pierre David, Suzanne M. Garland
Publikováno v:
Lancet (London, England). 384(9961)
Although adolescent girls are the main population for prophylactic human papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer can also be vaccinated. We report data from the interim analysis of the ongoing VIVIANE study, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161be939113faba5e300404d189e886f
https://pubmed.ncbi.nlm.nih.gov/26065038
https://pubmed.ncbi.nlm.nih.gov/26065038
Autor:
Mark H, Einstein, Mira, Baron, Myron J, Levin, Archana, Chatterjee, Bradley, Fox, Sofia, Scholar, Jeffrey, Rosen, Nahida, Chakhtoura, Dorothée, Meric, Francis J, Dessy, Sanjoy K, Datta, Dominique, Descamps, Gary, Dubin, Michael W, Warren
Publikováno v:
Human vaccines. 7(12)
In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18–26, 27–35, 36–45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8092d36fe214678c7981e7a0ac27d411
https://pubmed.ncbi.nlm.nih.gov/22048173
https://pubmed.ncbi.nlm.nih.gov/22048173
Autor:
Victoria Birlutiu, Sorin Man, Antonio Perino, Florence Thomas, Pavol Jarcuska, Radu Vlădăreanu, Susanna Esposito, Kurt Dobbelaere, Dominique Descamps, Dorothée Meric
BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4882c2f153ba6692ba631804eed15c87
http://hdl.handle.net/10447/78252
http://hdl.handle.net/10447/78252
